Compound profile

Cerebrolysin

Porcine brain-derived peptide mixture

A mixture of low-molecular-weight peptides and amino acids derived from porcine brain, used clinically outside the US for stroke and dementia, with a mixed evidence base.

Reviewed for accuracy · Last reviewed July 8, 2026
ClassPorcine brain-derived peptide and amino acid mixture
RouteIntravenous infusion or intramuscular injection
Trial range10 to 50 mL per day, in courses
StatusNot FDA-approved; used clinically abroad

Overview

Cerebrolysin is not a single molecule but a standardized mixture of low-molecular-weight peptides and free amino acids prepared from porcine brain tissue. It is proposed to have neurotrophic and neuroprotective activity, and in several countries (Russia, Eastern Europe, China, and other Asian and post-Soviet states) it is marketed and administered clinically for acute ischaemic stroke, vascular dementia, and traumatic brain injury. It is not approved by the FDA and is not sold in the United States.

The clinical evidence is genuinely mixed and often low in quality. A Cochrane review of acute ischaemic stroke found no reliable benefit on death or disability and flagged a possible increase in non-fatal serious adverse events at higher doses. A separate Cochrane review in vascular dementia reported apparent gains in cognition and function, but rated the underlying trials as heterogeneous and at high risk of bias. A small randomized traumatic brain injury trial was only suggestive. The honest reading is that benefit remains unproven and contested.

Dosing

Cerebrolysin is administered by professionals as intravenous infusions or intramuscular injections in courses. Trials used roughly 10 to 50 mL per day; there is no self-administered protocol and no FDA-approved dose.

Read the full Cerebrolysin dosage guide →

Side effects

Reported adverse events are generally mild (agitation, dizziness, injection-site reactions), with overall rates similar to placebo in reviews, though one stroke review flagged more non-fatal serious events at higher doses.

Read the full Cerebrolysin side effects guide →

Storage

Cerebrolysin is supplied as ampoules or vials handled in a clinical setting; storage follows the manufacturer's product information rather than a reconstitution protocol. See the full storage & safety guide for general handling and disposal basics.

FAQ

Is cerebrolysin FDA-approved?No. It is used clinically in several countries outside the United States, but it is not approved by the FDA and is not marketed in the US.
Does cerebrolysin actually work?The evidence is mixed. A Cochrane stroke review found no reliable benefit, while a Cochrane vascular dementia review reported apparent gains from weak, high-risk-of-bias trials. Benefit remains unproven.
How is it given?As intravenous infusions or intramuscular injections administered by healthcare professionals in courses, typically 10 to 50 mL per day depending on the setting studied.

References

  1. Cerebrolysin for acute ischaemic strokeCochrane Database of Systematic Reviews · 2020 · PMID 32662068 · DOI 10.1002/14651858.CD007026.pub6
  2. Cerebrolysin for vascular dementiaCochrane Database of Systematic Reviews · 2019 · PMID 31710397 · DOI 10.1002/14651858.CD008900.pub3
  3. Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I, a randomized, placebo-controlled, double-blind, Asian-Pacific trialNeurological Sciences · 2020 · PMID 31494820 · DOI 10.1007/s10072-019-04053-5
Tracking a research question about cerebrolysin? PepHub can help you keep sources and notes in one place.Learn more →

This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.